Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 10 drugs with upcoming expirations

Activity

Recent Activity

Last 14 days

Sep 19, 2026

Recruiting

A Phase 4, Randomized, Open Label Study to Evaluate the Safety and Tolerability of Twice Daily Xanomeline/Trospium Chloride (KarXT) With Prophylactic and PRN Antiemetic Use in Healthy Volunteers

Sep 15, 2026

Recruiting

A Phase 3 Double-blind, Placebo-controlled Randomized Withdrawal Maintenance Trial of KarXT Treatment in Participants With Schizophrenia

Earlier

Sep 5, 2026TrialA Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease

Aug 29, 2026TrialA Phase 3 Multicenter, Open-label Study to Assess the Long-term Safety and Tolerability of KarXT in Adolescents (13 to 17 Years of Age) With Schizophrenia and KarXT+KarX-EC in Children and Adolescents (5 to 17 Years of Age) With Irritability Associated With Autism Spectrum Disorder

Aug 27, 2026TrialA Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease

Aug 18, 2026TrialA Phase 3, Randomized, Double-Blind, Placebo-Controlled Relapse Prevention Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease

Aug 13, 2026FDAAzatiq — ZENBEXUS

Aug 1, 2026TrialAn Open-label Extension Study to Assess the Long-term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia

4 more events

Jul 23, 2026TrialA Phase 1, 3-part, Open-label Study to Evaluate the Effects of KarXT Administration on the Pharmacokinetics of Midazolam, Fexofenadine, and Digoxin in Healthy Adult Participants

Jul 22, 2026FDARevlimid — REVLIMID

Jul 7, 2026TrialOpen-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)

Jun 30, 2026FDASotyktu — SOTYKTU

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Regulatory

Regulatory Timeline

20233 events

FDADec 19

Camzyos — CAMZYOS

Application NDA214998

FDADec 5

Sprycel — PHYRAGO

Application NDA216099 (NDA)

FDANov 15

Augtyro — AUGTYRO

Application NDA218213 (NDA)

20249 events

FDADec 5

Reyataz — REYATAZ

Application NDA021567

FDADec 5

Reyataz — REYATAZ

Application NDA206352

FDAAug 30

Zeposia — ZEPOSIA

Application NDA209899

FDAAug 30

Zeposia — ZEPOSIA

Application NDA209899

FDAJul 31

Sprycel — SPRYCEL

Application NDA021986

FDAJun 21

Krazati — KRAZATI

Application NDA216340

FDAJun 5

Zeposia — ZEPOSIA

Application NDA209899

FDAJun 5

Zeposia — ZEPOSIA

Application NDA209899

FDAApr 30

Camzyos — CAMZYOS

Application NDA214998

20252 events

FDAOct 27

Sotyktu — SOTYKTU

Application NDA214958

FDAApr 17

Camzyos — CAMZYOS

Application NDA214998

20266 events

FDAAug 13

Azatiq — ZENBEXUS

Application NDA221075 (NDA)

FDAJul 22

Revlimid — REVLIMID

Application NDA021880

FDAJun 30

Sotyktu — SOTYKTU

Application NDA214958

FDAApr 27

Revlimid — REVLIMID

Application NDA021880

FDAMar 25

Krazati — KRAZATI

Application NDA216340

FDAMar 6

Sotyktu — SOTYKTU

Application NDA214958

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)